Hospital end users ranked the CVIS and hemodynamic systems they use, shedding light on their working relationships with IT vendors. 

The VIRTUE and POLARIS studies are both focused on evaluating how the Varipulse PFA Platform performs in a variety of clinical scenarios. 

TAVR continues to gain momentum as a go-to treatment option for severe AS, making it more important than ever to investigate long-term outcomes. This latest analysis, published in European Heart Journal, focused on 280 patients randomized to undergo either transcatheter or surgical aortic valve replacement.

One of the world's leading heart hospitals is seeing significant growth. This represents the first time it has hired four new cardiothoracic surgeons in a single 12-month period. 

Researchers explored the potential of an alternate way to perform PFA on patients with persistent AFib, presenting their findings live at AF Symposium 2024 in Boston.

The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation. 

The group's annual meeting heads to Atlanta this April. TAVR, GLP-1 agonists, medical imaging guidance and blood pressure control are just some of the topics that will be presented during late-breaking sessions.

The two neighboring practices have joined forces to provide improved cardiovascular care for patients throughout the Sunshine State.